‘’There’s no way in hell the U.S. tries this on monkeys, let alone people,’’ a Trump official told reporters in August.
The Sputnik V drug bypassed traditional steps in testing before its release. Even in Russia itself, many of the people shied away from getting the drug after they availed it to the public in December.
However, Sputnik V – named after the world’s first satellite – is starting to look like it could be a global success story. The well-respected British medical publisher, The Lancet, last week gave the vaccine a boost with its review of the drug.
The journal found that the vaccine had a 91.6% efficacy 21 days after the first shot. And for the elderly above 60 years, it had a 91.8% efficacy. This placed the Sputnik V vaccine on par with the celebrated Pfizer-BioNTech and Moderna vaccines.
Over 12 countries have so far approved the vaccine for use. Many others are now likely to follow since Lancet approved the drug.
Sputnik V is also considerably cheaper compared to its western competitors. It also does not require that ultra-cold kind of storage making it easier to distribute in developing countries.
‘’This is a watershed moment for us.’’ Kirill Dmitrev, chief executive of the state-run Russian Direct Investment Fund, which is behind both Sputnik V’s development and rollout.
- Peru Suspends Chinese Clinical Trials Of The Covid Vaccine
- U.S Set To Distribute Covid-19 Vaccines Directly To Pharmacies Across The Country
- UK Grants AstraZeneca Approval For Its Coronavirus Vaccine
Please use the button below to contribute to Newslex Point, Inc. using a credit card or via PayPal.